ArticleNews reportPHN-05792026-11-03 07:37 CT

MOD GRF 1-29 Explained: The Growth Hormone Peptide Behind the Headlines

Source · Iredell Free News

TLDR

Iredell Free News examines MOD GRF 1-29, a growth hormone-releasing peptide with four amino acid modifications. The article reports that it is not FDA-approved and lacks large, long-term trials establishing safety or effectiveness; most published human evidence concerns the distinct, longer-acting CJC-1295 with DAC.

01—Key points

01The article says controlled human trials of MOD GRF 1-29 itself are very limited.
02Human studies of CJC-1295 with DAC measured growth hormone and IGF-1 increases, not demonstrated improvements in strength, body composition or health.
03According to the article, MOD GRF 1-29 is excluded from the October 2026 HHS enforcement policy covering six compounded peptides.

Why it matters Editorial

The article highlights the distinction between evidence of increased hormone levels and evidence of clinical benefit, while separating closely related peptide formulations.

Read the original at Iredell Free News↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.